Neurocrine Biosciences revenue and financials
In the fiscal year ended December 2025, Neurocrine Biosciences reported revenue of $2.86B (+21.45% year over year). Net income was $478.6M, a net margin of 16.7%.
Fiscal year ending in December. Sources and method on the page How we analyse stocks.
At a glance
- Revenue growth
- +21.45%
- 2025 vs 2024
- Net income growth
- +40.23%
- 2025 vs 2024
- Net margin
- 16.7%
- 2024: 14.5%
How Neurocrine Biosciences is changing
Calculated from the annual statements; each fiscal year is labelled with the year it ends.
Revenue grew 22.3% a year on average over the last 5 years
Compound annual growth rate: from $1.05B in 2020 to $2.86B in 2025.
Revenue has grown for 9 fiscal years in a row
Each fiscal year compared with the one before, up to 2025.
Operating margin rose from 16.7% to 21.6%
Operating income over revenue, 2022 → 2025: 4.9 percentage points.
Profits turn into cash: free cash flow equal to 156% of net income
Totals for fiscal years 2023–2025: free cash flow $1.67B, net income $1.07B.
Shares outstanding up 4.8% in 5 years
Average diluted shares, 2020 → 2025: with more shares, each one represents a smaller stake in the company (dilution).
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 2,861 | 2,355 | 1,887 | 1,489 | 1,134 | 1,046 | 788 | 451 | 162 | 15.0 |
| Cost of revenue | 52.1 | 34.0 | 39.7 | 23.2 | 14.3 | 10.1 | 207 | 4.9 | 1.3 | 0.0 |
| Gross profit | 1,793 | 1,590 | 1,282 | 1,002 | 791 | 761 | 581 | 291 | 68.5 | -20.9 |
| Selling, general and administrative | 1,156 | 993 | 888 | 753 | 583 | 433 | 354 | 249 | 170 | 68.1 |
| Research and development | 1,016 | 731 | 565 | 464 | — | — | — | 161 | 122 | 94.3 |
| Operating income | 619 | 571 | 251 | 249 | 103 | 163 | 72.3 | 36.8 | -131 | -147 |
| EBIT | 637 | 597 | 395 | 249 | 208 | 328 | 227 | 41.6 | -101 | -147 |
| EBITDA | 667 | 624 | 416 | 265 | 219 | 336 | 234 | 45.6 | -99.0 | -146 |
| Interest expense | — | 127 | 4.6 | 7.1 | 25.8 | 32.8 | 32.0 | 30.5 | 19.5 | 0.0 |
| Pre-tax income | 705 | 486 | 332 | 214 | 101 | 107 | 46.5 | 21.8 | -143 | -141 |
| Income tax | 227 | 145 | 82.4 | 59.4 | 11.8 | -301 | 9.5 | 0.7 | 0.0 | 0.0 |
| Net income | 479 | 341 | 250 | 155 | 89.6 | 407 | 37.0 | 21.1 | -143 | -141 |
| Net income to common shareholders | 479 | 341 | 250 | 155 | 89.6 | 407 | 37.0 | 21.1 | -143 | -141 |
| Basic EPS | 4.81 | 3.40 | 2.56 | 1.61 | 0.95 | 4.38 | 0.40 | 0.23 | -1.62 | -1.63 |
| Diluted EPS | 4.67 | 3.29 | 2.47 | 1.56 | 0.92 | 4.16 | 0.39 | 0.22 | -1.62 | -1.63 |
| Average shares (basic) | 99.5 | 100 | 97.7 | 95.8 | 94.6 | 93.1 | 91.6 | 90.2 | 88.1 | 86.7 |
| Average shares (diluted) | 103 | 104 | 101 | 98.9 | 97.9 | 97.8 | 95.7 | 95.4 | 88.1 | 86.7 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 1,123 | 959 | 815 | 806 | 795 | 688 | 573 | 628 | 622 | 590 | 515 | 515 |
| Cost of revenue | 372 | 347 | 310 | 276 | 263 | 255 | 272 | 195 | 203 | 200 | 167 | 146 |
| Gross profit | 751 | 612 | 505 | 530 | 532 | 433 | 300 | 433 | 419 | 390 | 348 | 369 |
| Selling, general and administrative | 357 | 383 | 319 | 303 | 292 | 286 | 277 | 288 | 234 | 228 | 243 | 219 |
| Research and development | 352 | 327 | 296 | 258 | 250 | — | — | — | — | — | — | — |
| Operating income | 359 | 213 | 186 | 227 | 239 | 146 | 23.7 | 145 | 185 | 162 | 105 | 150 |
| EBIT | 359 | 213 | 186 | 227 | 239 | 146 | 23.7 | 145 | 185 | 162 | 105 | 150 |
| EBITDA | 403 | 238 | 193 | 235 | 247 | 153 | 31.3 | 152 | 191 | 169 | 112 | 156 |
| Interest expense | 0.3 | 2.9 | — | — | 0.0 | 0.0 | — | — | — | — | — | — |
| Pre-tax income | 284 | 162 | 247 | 239 | 292 | 160 | 14.7 | 163 | 190 | 98.6 | 34.5 | 198 |
| Income tax | 77.2 | 17.8 | 48.9 | 85.7 | 82.3 | 52.0 | 6.8 | 59.5 | 60.5 | 33.6 | -8.9 | 50.5 |
| Net income | 207 | 144 | 198 | 154 | 210 | 108 | 7.9 | 103 | 130 | 65.0 | 43.4 | 148 |
| Net income to common shareholders | 207 | 144 | 198 | 154 | 210 | 108 | 7.9 | 103 | 130 | 65.0 | 43.4 | 148 |
| Basic EPS | 2.03 | 1.43 | 1.97 | 1.54 | 2.11 | 1.09 | 0.08 | 1.03 | 1.28 | 0.64 | 0.43 | 1.50 |
| Diluted EPS | 1.96 | 1.39 | 1.91 | 1.48 | 2.04 | 1.06 | 0.08 | 1.00 | 1.24 | 0.63 | 0.42 | 1.45 |
| Average shares (basic) | 102 | 101 | 101 | 99.9 | 99.4 | 99.0 | 99.7 | 100 | 101 | 101 | 99.8 | 98.4 |
| Average shares (diluted) | 105 | 104 | 103 | 104 | 103 | 101 | 103 | 103 | 104 | 104 | 104 | 102 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 4,632 | 3,719 | 3,251 | 2,369 | 2,073 | 1,735 | 1,306 | 993 | 818 | 365 |
| Current assets | 2,523 | 1,725 | 1,607 | 1,454 | 973 | 1,016 | 831 | 738 | 555 | 310 |
| Cash and equivalents | 713 | 233 | 251 | 263 | 341 | 187 | 112 | 142 | 255 | 83.3 |
| Short-term investments | 767 | 843 | 781 | 726 | 371 | 614 | 558 | 509 | 261 | 224 |
| Receivables | 687 | 479 | 439 | 350 | 186 | 157 | 127 | 57.4 | 31.1 | — |
| Inventory | 69.0 | 57.4 | 38.3 | 35.1 | 30.5 | 28.0 | 17.3 | 10.9 | 1.0 | — |
| Net property, plant and equipment | 545 | 592 | 347 | 146 | 156 | 127 | 116 | 33.9 | 10.8 | 6.3 |
| Goodwill | — | 5.7 | 5.8 | 5.4 | 0.0 | — | — | — | — | — |
| Other intangible assets | — | 36.5 | 35.5 | 37.2 | — | — | — | — | — | — |
| Long-term investments | 1,184 | 864 | 849 | 402 | 624 | 265 | 356 | 216 | 247 | 43.5 |
| Current liabilities | 743 | 508 | 655 | 538 | 246 | 187 | 565 | 88.2 | 54.4 | 30.4 |
| Accounts payable | 105 | 99.9 | 133 | 67.3 | 51.5 | 39.4 | 41.4 | 38.4 | 5.6 | 5.1 |
| Long-term debt | — | — | — | — | 335 | 318 | — | 388 | 370 | — |
| Total debt | 471 | 455 | 428 | 263 | 440 | 412 | 496 | 388 | 370 | — |
| Total liabilities | 1,378 | 1,129 | 1,019 | 661 | 699 | 609 | 669 | 512 | 445 | 50.2 |
| Total equity (incl. minority) | 3,253 | 2,590 | 2,232 | 1,708 | 1,374 | 1,126 | 637 | 481 | 372 | 315 |
| Retained earnings | 448 | 29.2 | -157 | -407 | -636 | -725 | -1,133 | -1,178 | -1,199 | -1,056 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 5,627 | 5,359 | 4,906 | 4,632 | 4,266 | 3,890 | 3,688 | 3,719 | 3,535 | 3,305 | 3,472 | 3,251 |
| Current assets | 2,008 | 1,638 | 2,436 | 2,523 | 2,158 | 1,749 | 1,638 | 1,725 | 1,877 | 1,670 | 1,799 | 1,607 |
| Cash and equivalents | 642 | 332 | 267 | 713 | 340 | 264 | 194 | 233 | 349 | 140 | 396 | 251 |
| Short-term investments | 96.4 | 57.4 | 1,050 | 767 | 775 | 712 | 749 | 843 | 879 | 899 | 814 | 781 |
| Receivables | 959 | 887 | 768 | 687 | 728 | 596 | 516 | 479 | 481 | 468 | 451 | 439 |
| Inventory | 66.1 | 104 | 64.5 | 69.0 | 69.3 | 56.9 | 59.1 | 57.4 | 45.8 | 42.5 | 37.2 | 38.3 |
| Net property, plant and equipment | 529 | 539 | 538 | 545 | 566 | 584 | 589 | 592 | 337 | 343 | 346 | 347 |
| Goodwill | 501 | 501 | — | — | — | — | — | — | 6.1 | — | — | 5.8 |
| Other intangible assets | 2,191 | 2,226 | — | — | 35.7 | 37.2 | 36.4 | — | 34.5 | 33.5 | 34.3 | 35.5 |
| Long-term investments | 147 | 239 | 1,477 | 1,184 | 1,117 | 961 | 910 | 864 | 771 | 781 | 864 | 849 |
| Current liabilities | 985 | 875 | 832 | 743 | 638 | 546 | 523 | 508 | 430 | 399 | 713 | 655 |
| Accounts payable | 151 | 142 | 120 | 105 | 120 | 105 | 110 | 99.9 | 95.7 | 107 | 87.3 | 133 |
| Total debt | 392 | 462 | 464 | 471 | 480 | 490 | 493 | 455 | 286 | 292 | 411 | — |
| Total liabilities | 1,749 | 1,666 | 1,499 | 1,378 | 1,262 | 1,196 | 1,152 | 1,129 | 816 | 796 | 1,086 | 1,019 |
| Total equity (incl. minority) | 3,879 | 3,694 | 3,407 | 3,253 | 3,004 | 2,694 | 2,536 | 2,590 | 2,719 | 2,509 | 2,386 | 2,232 |
| Retained earnings | 838 | 724 | 590 | 448 | 294 | 84.5 | -5.3 | 29.2 | 81.1 | -48.7 | -114 | -157 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 783 | 595 | 390 | 339 | 257 | 229 | 147 | 101 | -94.3 | -106 |
| Depreciation and amortization | 26.0 | 23.5 | 17.8 | 15.1 | 10.9 | 8.6 | 7.4 | 4.0 | 2.4 | 1.5 |
| Capital expenditure | -34.0 | -38.2 | -28.3 | -16.5 | -23.4 | -10.9 | -14.7 | -24.8 | -6.9 | -4.1 |
| Investing cash flow | -264 | -127 | -467 | -177 | -130 | 4.1 | -211 | -243 | -251 | 113 |
| Financing cash flow | -38.3 | -487 | 65.3 | -234 | 27.4 | -158 | 32.4 | 29.5 | 517 | 2.4 |
| Share repurchases | -168 | -300 | 0.0 | 0.0 | — | — | — | — | — | — |
| Debt issued | — | — | — | — | — | — | — | — | 503 | — |
| Debt repaid | 0.0 | -309 | 0.0 | -279 | -0.1 | -187 | — | — | — | — |
| Effect of exchange rates | 0.0 | 0.0 | 0.3 | -1.3 | — | — | — | — | — | — |
| Net change in cash | 480 | -18.1 | -11.6 | -73.3 | 154 | 74.8 | -31.7 | -112 | 171 | 9.2 |
| Free cash flow | 749 | 557 | 362 | 323 | 233 | — | — | — | — | — |
| Levered free cash flow | 398 | 507 | 439 | 248 | 266 | 279 | 205 | 49.1 | -37.7 | -59.8 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 395 | 136 | 146 | 388 | 228 | 102 | 64.8 | 243 | 158 | 64.6 | 130 | 124 |
| Depreciation and amortization | 44.0 | 24.8 | 7.3 | 7.5 | 7.7 | 7.3 | 7.6 | 7.1 | 6.5 | 7.3 | 6.2 | 5.7 |
| Capital expenditure | -11.6 | -7.8 | -9.1 | 2.4 | -13.2 | -12.5 | -10.7 | -7.3 | -8.1 | -11.6 | -11.2 | -5.4 |
| Investing cash flow | -11.1 | -135 | -506 | -52.9 | -197 | -29.0 | 14.2 | -68.3 | 24.7 | -28.2 | -55.0 | -202 |
| Financing cash flow | -75.0 | 63.4 | -86.1 | 37.3 | 45.6 | -3.3 | -118 | -290 | 26.4 | -293 | 69.9 | 35.4 |
| Share repurchases | -100 | -14.7 | -110 | 0.0 | 0.0 | -17.7 | -150 | -300 | — | — | — | — |
| Debt issued | 0.0 | 600 | — | — | 0.0 | — | — | — | — | — | — | — |
| Debt repaid | 0.0 | -600 | — | 0.0 | 0.0 | — | — | 0.0 | 0.0 | -309 | — | — |
| Effect of exchange rates | — | — | — | 0.0 | -0.2 | 0.2 | — | -0.3 | 0.3 | — | — | 0.3 |
| Net change in cash | 309 | 64.4 | -447 | 373 | 76.2 | 69.9 | -38.9 | -116 | 209 | -257 | 145 | -42.6 |
| Free cash flow | 384 | 129 | 137 | 391 | 214 | 89.5 | 54.1 | 235 | 150 | 53.0 | 119 | 118 |
| Levered free cash flow | 344 | 121 | 181 | 313 | -35.1 | 25.2 | -11.7 | 270 | -10.4 | -87.9 | 251 | 92.5 |
Financial statements of similar companies
Companies in the group: same industry, similar size
